WHAT IS CLAIMED IS:

1. A compound of the formula I:



I

wherein:

R^1 is selected from one or more of the groups consisting of:

(1) hydrogen,

(2) C_{1-6}alkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxy or phenyl,

(3) -O-C_{1-6}alkyl,

(4) halogen,

(5) phenyl, which is substituted with R^{2a}, R^{2b} and R^{2c},

(6) heterocycle, which is substituted with R^{2a}, R^{2b} and R^{2c},

(7) -CN,

(8) $-CO_2R^9$,

wherein R^9 is independently selected from:

(a) hydrogen,

(b) -C_{1-6}alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(c) benzyl, and

(d) phenyl,

(9) $-SO_2R^9$,

(10) $-SO_2-NR^{10}R^{11}$,

wherein R^{10} and R^{11} are independently selected from:

(a) hydrogen,

(b) -C_{1-6}alkyl, which is unsubstituted or substituted with hydroxy, 1-6 fluoro or -$NR^{12}R^{13}$, where R^{12} and R^{13} are independently selected from hydrogen and -C_{1-6}alkyl, and whereR^{10} and R^{11} may be joined to form an azetidinyl ring,

(c) -C_{3-6}cycloalkyl, which is unsubstituted or substituted with hydroxy, 1-6 fluoro or -$NR^{12}R^{13}$,

(d) benzyl,

(e) phenyl, and

(11) -$CONR^{10}R^{11}$;

R^2 is selected from the group consisting of:

(1) phenyl, which is substituted with R^{2a}, R^{2b} and R^{2c},

(2) heterocycle, which is substituted with R^{2a}, R^{2b} and R^{2c},

(3) C_{1-8}alkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxy, -$NR^{10}R^{11}$, phenyl or heterocycle, where the phenyl or heterocycle is substituted with R^{2a}, R^{2b} and R^{2c},

(4) C_{3-6}cycloalkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxy or -$NR^{10}R^{11}$, and

(5) -C_{1-6}alkyl-(C_{3-6}cycloalkyl), which is unsubstituted or substituted with 1-6 halogen, hydroxy or -$NR^{10}R^{11}$;

R^{2a}, R^{2b} and R^{2c} are independently selected from the group consisting of:

(1) hydrogen,

(2) halogen,

(3) -C_{1-6}alkyl, which is unsubstituted or substituted with:

(a) 1-6 halogen,

(b) phenyl,

(c) C_{3-6}cycloalkyl, or

(d) -$NR^{10}R^{11}$,

(4) -O-C_{1-6}alkyl, which is unsubstituted or substituted with 1-6 halogen,

(5) hydroxy,

(6) -SCF_3,

(7) -$SCHF_2$,

(8) -SCH_3,

(9) -CO_2R^9,

(10) -CN,

(11) -SO_2R^9,

(12) -SO_2-$NR^{10}R^{11}$,

(13) -$NR^{10}R^{11}$,

(14) -$CONR^{10}R^{11}$, and

(15) $-NO_2$;

R^3 is selected from the group consisting of:

(1) C_{1-6}alkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxyl, $-NR^{10}R^{11}$, or heterocycle, which is substituted with R^{2a}, R^{2b} and R^{2c},

(2) C_{3-6}cycloalkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxyl or $-NR^{10}R^{11}$,

(3) $-C_{1-6}$alkyl-(C_{3-6}cycloalkyl), which is unsubstituted or substituted with 1-6 halogen, hydroxy or $-NR^{10}R^{11}$, and

(4) $-NR^{10}R^{11}$, and

(5) heterocycle, which is substituted with R^{2a}, R^{2b} and R^{2c};

R^4 and R^5 are independently selected from the group consisting of:

(1) hydrogen, and

(2) C_{1-6}alkyl, which is unsubstituted or substituted with halogen or hydroxyl,

or R^4 and R^5 taken together form a C_{3-6}cycloalkyl ring;

R^6 is selected from the group consisting of:

(1) hydrogen, and

(2) C_{1-6}alkyl;

W, X, Y and Z are independently selected from C or N, with the proviso that at least two of W, X, Y and Z are C, to form a pyridine, oxo-dihydropyridine, pyridazine, pyrimidine, pyrazine, 1,2,4-triazine or 1,3,5-triazine ring;

A is selected from the group consisting of:

(1) -O-, and

(2) $-NR^{10}-$;

m is zero or one, whereby when m is zero R^2 is attached directly to the carbonyl;

and pharmaceutically acceptable salts thereof.

2. The compound of Claim 1 of the formula Ia:



Ia

or a pharmaceutically acceptable salt thereof.

3. The compound of Claim 1 wherein R^1 is selected from the group consisting of:

(1) hydrogen,
(2) C_{1-3}alkyl,
(3) fluoro,
(4) -CF_3,
(5) -morpholinyl, and
(6) -O-C_{1-3}alkyl.

4. The compound of Claim 3 wherein R^1 is hydrogen or methyl.

5. The compound of Claim 1 of the formula Ib:



Ib

wherein R^4 is C_{1-6}alkyl; or a pharmaceutically acceptable salt thereof or an individual enantiomer or diastereomer thereof.

6. The compound of Claim 1 wherein R^4 is C_{1-3}alkyl and R^5 is hydrogen or C_{1-3}alkyl.

7. The compound of Claim 6 wherein R^4 is C_{1-3}alkyl in the (S) configuration and R^5 is hydrogen.

8. The compound of Claim 6 wherein R^4 is methyl and R^5 is hydrogen.

9. The compound of Claim 1 wherein R^4 is methyl and R^5 is methyl.

10. The compound of Claim 1 wherein R^4 is hydrogen and R^5 is hydrogen.

11. The compound of Claim 1 of the formula Ic:



Ic

or a pharmaceutically acceptable salt thereof.

12. The compound of Claim 1 wherein R^2 is selected from the group consisting of:

(1) phenyl, which is substituted with R^{2a}, R^{2b} and R^{2c},

(2) thienyl, which is substituted with R^{2a}, R^{2b} and R^{2c},

(3) C_{1-8}alkyl, which is unsubstituted or substituted with 1-6 halogen, phenyl or $-NR^{10}R^{11}$, where the phenyl is substituted with R^{2a}, R^{2b} and R^{2c},

(4) C_{3-6}cycloalkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxy or $-NR^{10}R^{11}$, and

R^{2a}, R^{2b} and R^{2c} are independently selected from the group consisting of:

(1) hydrogen,

(2) halogen,

(3) $-C_{1-6}$alkyl,

(4) $-O-C_{1-6}$alkyl,

(5) $-CF_3$,

(6) $-OCF_3$,

(7) $-OCHF_2$,

(8) $-SCF_3$,

(9) $-SCHF_2$, and

(10) $-NH_2$.

13. The compound of Claim 12 wherein R^2 is phenyl or thienyl and R^{2a}, R^{2b} and R^{2c} are independently selected from the group consisting of:

(1) hydrogen,
(2) halogen,
(3) -C_{1-6}alkyl,
(4) -O-C_{1-6}alkyl,
(5) -CF_3,
(6) -OCF_3,
(7) -$OCHF_2$,
(8) -SCF_3,
(9) -$SCHF_2$, and
(10) -NH_2.

14. The compound of Claim 13 wherein R^2 is phenyl and R^{2a}, R^{2b} and R^{2c} are independently selected from the group consisting of:

(1) hydrogen,
(2) fluoro,
(3) chloro,
(4) bromo,
(5) -OCH_3,
(6) -CF_3, and
(7) -NH_2.

15. The compound of Claim 1 of the formula If:



If

or a pharmaceutically acceptable salt thereof.

16. The compound of Claim 1 of the formula Ig:



Ig

or a pharmaceutically acceptable salt thereof.

17. The compound of Claim 1 of the formula Ih:



Ih

or a pharmaceutically acceptable salt thereof.

18. The compound of Claim 1 wherein R^3 is selected from C_{1-6}alkyl, C_{1-6}alkyl-fluoro, C_{3-6}cycloalkyl, C_{1-6}alkyl-cyclopropyl, -NH(C_{1-6}alkyl), -N(C_{1-6}alkyl)(C_{1-6}alkyl) or azedinyl, which is unsubstituted or substituted with fluoro.

19. The compound of Claim 18 wherein R^3 is $-CH_2CH_3$.

20. The compound of Claim 18 wherein R^3 is $-(CH_2)_2CH_3$.

21. The compound of Claim 18 wherein R^3 is $-CH_2$-cyclopropyl.

22. A compound which is selected from the group consisting of:

2-chloro-3,6-difluoro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{(1S)-1-[1-(ethylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;

2-chloro-3,6-difluoro-N-{1-methyl-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;

2-chloro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2,6-dichloro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}-benzamide;

2-bromo-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2-chloro-6-fluoro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2-amino-6-chloro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2-fluoro-6-methoxy-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2-chloro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2-fluoro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}-6-(trifluoromethyl)benzamide;

2,6-difluoro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2-chloro-6-fluoro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2,6-dichloro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2-chloro-3,6-difluoro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2-chloro-4-fluoro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

4-chloro-2-fluoro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{[4-(4-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide

2,4-dichloro-N-{[1-(methylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{[1-(isopropylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide

2,4-dichloro-N-{[1-(ethylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{[1-(cyclopropylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{[1-(propylsulfonyl)-4-pyridin-3-ylpiperidin-4-yl]methyl}benzamide;

2,6-dichloro-N-{[1-(propylsulfonyl)-4-pyridin-3-ylpiperidin-4-yl]methyl}benzamide

2,4-dichloro-N-{[1-(propylsulfonyl)-4-pyridin-4-ylpiperidin-4-yl]methyl}benzamide;

2-chloro-6-fluoro-N-{[1-(propylsulfonyl)-4-pyridin-4-ylpiperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-({1-[(dimethylamino)sulfonyl]-4-pyridin-2-ylpiperidin-4-yl}methyl)benzamide;

4,4,4-trifluoro-3-methyl-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}butanamide;

2-chloro-6-fluoro-N-{[4-(6-morpholin-4-ylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-{[4-(6-morpholin-4-ylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
2,4,5-trifluoro-N-{[4-(6-methoxypyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
2,4-dichloro-5-fluoro-N-{[4-(6-methoxypyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}cyclohexanecarboxamide;
2-chloro-N-{[1-(cyclopropylsulfonyl)-4-(6-methylpyridin-2-yl)piperidin-4-yl]methyl}-3,6-difluorobenzamide;
N-{[1-(ethylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}-2,4-difluorobenzamide;
N-(sec-butyl)-N'-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}urea;
N-(4-bromophenyl)-N'-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}urea;
3-fluorobenzyl {[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}carbamate;
2-chlorobenzyl {[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}carbamate;
2,4-dichloro-N-{1-methyl-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
2-chloro-3,6-difluoro-N-{1-methyl-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
N-{1-methyl-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}-2-(trifluoromethoxy)benzamide;
2,4-dichloro-N-{1-methyl-1-[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]ethyl}benzamide;
2-chloro-3,6-difluoro-N-{1-methyl-1-[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]ethyl}benzamide;
2,4-dichloro-N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
2-chloro-3,6-difluoro-N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
2,4-dichloro-N-{(1S)-1-[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]ethyl}benzamide;
2-chloro-3,6-difluoro-N-{(1S)-1-[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]ethyl}benzamide;
4,4,4-trifluoro-3-methyl-N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}butanamide;
N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}thiophene-3-carboxamide;
N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}cyclopentane-carboxamide;
N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}cyclohexane-carboxamide;
2-ethyl-N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}butanamide;
2-methyl-N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}butanamide;
3,3,3-trifluoro-N-{(1S)-1-[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]ethyl}propanamide;
2,5-dichloro-N-{(1S)-1-[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]ethyl}thiophene-3-carboxamide;

4-bromo-N-{(1S)-1-[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]ethyl}thiophene-3-carboxamide;
2,5-dichloro-N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}thiophene-3-carboxamide;
4-bromo-N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}thiophene-3-carboxamide;
2-chloro-*N*-{[1-(propylsulfonyl)-4-pyrimidin-4-ylpiperidin-4-yl]methyl}benzamide;
2,4-dichloro-*N*-{[1-(propylsulfonyl)-4-pyrimidin-4-ylpiperidin-4-yl]methyl}benzamide;
2-chloro-3,6-difluoro-*N*-{[1-(propylsulfonyl)-4-pyrimidin-4-ylpiperidin-4-yl]methyl}benzamide;
2,4-dichloro-5-fluoro-*N*-{[1-(propylsulfonyl)-4-pyrimidin-4-ylpiperidin-4-yl]methyl}benzamide;
2-chloro-*N*-{(1*S*)-1-[1-(ethylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
2-chloro-*N*-{(1*S*)-1-[1-(ethylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}-3,6-difluorobenzamide;
2-chloro-*N*-{(1*S*)-1-[1-(ethylsulfonyl)-4-(6-methylpyridin-2-yl)piperidin-4-yl]ethyl}-3,6-difluorobenzamide;
2,4-dichloro-*N*-{(1*S*)-1-[1-(ethylsulfonyl)-4-(6-methylpyridin-2-yl)piperidin-4-yl]ethyl}benzamide;
2,4-dichloro -N-{1-methyl-1-[1-(azetidinesulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
2,4-dichloro-N-{1-methyl-1-[1-(3-fluoroazetidinesulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
2,4-dichloro-N-{1-methyl-1-[1-(3-fluoroazetidinesulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
2,4-dichloro -N-{1-methyl-1-[1-(azetidinesulfonyl)-4-(3-fluoropyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
2,4-dichloro-N-{1-methyl-1-[1-(ethylaminosulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
2,4-dichloro-N-{[1-[(ethylamino)sulfonyl]-4-(3-fluoropyridin-2-yl)piperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-{1-[1-(ethylaminosulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
2,4-dichloro-N-{1-[1-(ethylaminosulfonyl)-4-(3-fluoropyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
2,4-dichloro-N-{[4-(3-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-({1-(propylsulfonyl)-4-[6-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}methyl)benzamide;
2,4-dichloro-N-{[1-[(cyclopropylmethyl)sulfonyl]-4-(3-methylpyridin-2-yl)piperidin-4-yl]methyl}-benzamide;
2,4-dichloro-N-({1-(propylsulfonyl)-4-[4-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}methyl)benzamide;
2,4-dichloro-N-{[4-(3-chloropyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-{[4-(3-methoxypyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
2-chloro-N-{[4-(3-chloropyridin-2-yl)-1-(ethylsulfonyl)piperidin-4-yl]methyl}-3,6-difluorobenzamide;
2,4-dichloro-N-({1-[(cyclopropylmethyl)sulfonyl]-4-pyridin-2-ylpiperidin-4-yl}methyl)benzamide;
methyl [(4-{[(2,4-dichlorobenzoyl)amino]methyl}-4-pyridin-2-ylpiperidin-1-yl)sulfonyl]acetate;
2,4-dichloro-N-{[1-(ethylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-{[1-(propylsulfonyl)-4-pyrazin-2-ylpiperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-(1-{1-[(3-fluoropropyl)sulfonyl]-4-pyridin-2-ylpiperidin-4-yl}ethyl)benzamide;
2,4-dichloro-N-({1-[(3-fluoropropyl)sulfonyl]-4-pyridin-2-ylpiperidin-4-yl}methyl)benzamide;
2,4-dichloro-N-{[1-[(3-fluoropropyl)sulfonyl]-4-(3-fluoropyridin-2-yl)piperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-{[1-[(cyclopropylmethyl)sulfonyl]-4-(3-fluoropyridin-2-yl)piperidin-4-yl]methyl}
benzamide;
2,4-dichloro-N-{[4-(3-fluoropyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
2-chloro-3,5-difluoro -N-{[1-[(cyclopropylmethyl)sulfonyl]-4-(3-fluoropyridin-2-yl)piperidin-4-yl]methyl}benzamide;
2,4-dichloro-5-fluoro -N-{[1-[(cyclopropylmethyl)sulfonyl]-4-(3-fluoropyridin-2-yl)piperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-{1-[4-(3-fluoropyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]ethyl}benzamide;
2,4-dichloro-N-{[4-(6-trifluoromethylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
4-bromo-2-chloro-N-{[1-(ethylsulfonyl)-4-(3-fluoropyridin-2-yl)- piperidin-4-yl]methyl}benzamide;
N-(3-fluorobenzyl)-N'-{[1-(propylsulfonyl)-4-(6-trifluoromethylpyridin-2-yl)piperidin-4-yl]methyl}urea;
2,4-dichloro-N-{1-[1-(ethylsulfonyl)-4-(3-fluoropyridin-2-yl)- piperidin-4-yl]ethyl}benzamide;
2-bromo-4-fluoro-N-{[1-(ethylsulfonyl)-4-(3-fluoropyridin-2-yl)- piperidin-4-yl]methyl}benzamide;
2-chloro-3,6-difluoro-N-{[1-(ethylsulfonyl)-4-(3-fluoropyridin-2-yl)- piperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-{[1-(ethylsulfonyl)-4-(3-trifluoromethylpyridin-2-yl)- piperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-({1-[(3-fluoropropyl)sulfonyl]-4-(3-trifluoromethylpyridin-2-ylpiperidin-4-yl}methyl)benzamide;
2,4,6-trifluoro-N-{[1-(ethylsulfonyl)-4-(3-trifluoromethylpyridin-2-yl)- piperidin-4-yl]methyl}benzamide;
N-(sec-butyl)-N'-{[1-(propylsulfonyl)-4-(6-trifluoromethylpyridin-2-yl)piperidin-4-yl]methyl}urea;
2,4-dichloro-N-{[1-(ethylsulfonyl)-4-(3-trifluoromethylpyridin-2-yl)- piperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-{1-[4-(3-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-l]ethyl}benzamide;
N-{[4-(3-bromopyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}-2,4-dichlorobenzamide;
2,4-dichloro-N-{[4-(6-fluoropyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-{[4-(6-chloropyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-{[4-(6-oxo-1,6-dihydropyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-{[4-(3-hydroxypyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-{[(2[R,S],4[S,R])-2-methyl-1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-({1-(ethylsulfonyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}methyl)benzamide;
or a pharmaceutically acceptable salt thereof.

23. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

24. A method for inhibiting the glycine transporter GlyT1 in a mammal in need thereof which comprises the administration of an effective amount of the compound of Claim 1 or a pharmaceutically acceptable salt thereof.

25. A method for the manufacture of a medicament for inhibiting the glycine transporter GlyT1 in a mammal in need thereof comprising combining the compound of Claim 1 or a pharmaceutically acceptable salt thereof with a pharmaceutical carrier or diluent.

26. A method for treating a neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

27. A method for treating schizophrenia in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.